Free Trial
NASDAQ:TMCI

Treace Medical Concepts (TMCI) Stock Price, News & Analysis

Treace Medical Concepts logo
$2.01 +0.09 (+4.69%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$1.98 -0.03 (-1.49%)
As of 05/8/2026 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Treace Medical Concepts Stock (NASDAQ:TMCI)

Advanced

Key Stats

Today's Range
$1.88
$2.23
50-Day Range
$1.20
$2.23
52-Week Range
$1.17
$7.78
Volume
763,851 shs
Average Volume
989,702 shs
Market Capitalization
$130.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.77
Consensus Rating
Reduce

Company Overview

Treace Medical Concepts Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

TMCI MarketRank™: 

Treace Medical Concepts scored higher than 33% of companies evaluated by MarketBeat, and ranked 685th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Treace Medical Concepts has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 2 sell ratings.

  • Upside Potential

    Treace Medical Concepts has a consensus price target of $4.77, representing about 137.3% upside from its current price of $2.01.

  • Amount of Analyst Coverage

    Treace Medical Concepts has only been the subject of 2 research reports in the past 90 days.

  • Read more about Treace Medical Concepts' stock forecast and price target.
  • Earnings Growth

    Earnings for Treace Medical Concepts are expected to remain at ($0.92) per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Treace Medical Concepts is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Treace Medical Concepts is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Treace Medical Concepts has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for TMCI.
  • Dividend Yield

    Treace Medical Concepts does not currently pay a dividend.

  • Dividend Growth

    Treace Medical Concepts does not have a long track record of dividend growth.

  • News Sentiment

    Treace Medical Concepts has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Treace Medical Concepts this week, compared to 4 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Treace Medical Concepts insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    23.42% of the stock of Treace Medical Concepts is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    84.08% of the stock of Treace Medical Concepts is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Treace Medical Concepts' insider trading history.
Receive TMCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TMCI Stock News Headlines

Introducing The Early Bird Stock of the Day
What if the next Apple or Amazon landed in your inbox… tomorrow? Imagine getting the research, numbers, and expert opinions on a stock before everyone else even has a clue. It’s like having a backstage pass to the best concert in town—but for your portfolio.tc pixel
See More Headlines

TMCI Stock Analysis - Frequently Asked Questions

Treace Medical Concepts' stock was trading at $2.45 at the beginning of 2026. Since then, TMCI stock has decreased by 18.0% and is now trading at $2.01.

Treace Medical Concepts, Inc. (NASDAQ:TMCI) issued its earnings results on Friday, May, 8th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.03. The business earned $47.20 million during the quarter, compared to analysts' expectations of $45.96 million. Treace Medical Concepts had a negative net margin of 27.74% and a negative trailing twelve-month return on equity of 59.91%.
Read the conference call transcript
.

Treace Medical Concepts (TMCI) raised $180 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 11,250,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

Top institutional shareholders of Treace Medical Concepts include Dimensional Fund Advisors LP (0.30%), Abel Hall LLC (0.06%), Hsbc Holdings PLC (0.05%) and Chicago Partners Investment Group LLC (0.04%). Insiders that own company stock include John T Treace, James T Treace, Richard W Mott, Sean F Scanlan, Deepti Jain and F Barry Bays.
View institutional ownership trends
.

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Treace Medical Concepts investors own include American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
5/08/2026
Today
5/10/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:TMCI
CIK
1630627
Fax
N/A
Employees
250
Year Founded
N/A

Price Target and Rating

High Price Target
$7.00
Low Price Target
$3.00
Potential Upside/Downside
+137.3%
Consensus Rating
Reduce
Rating Score (0-4)
1.86
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.94)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$59 million
Net Margins
-27.74%
Pretax Margin
-27.74%
Return on Equity
-59.91%
Return on Assets
-28.44%

Debt

Debt-to-Equity Ratio
0.64
Current Ratio
4.31
Quick Ratio
3.13

Sales & Book Value

Annual Sales
$212.69 million
Price / Sales
0.61
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.37 per share
Price / Book
1.47

Miscellaneous

Outstanding Shares
64,780,000
Free Float
49,612,000
Market Cap
$130.21 million
Optionable
Optionable
Beta
1.10
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:TMCI) was last updated on 5/10/2026 by MarketBeat.com Staff.
From Our Partners